2,3-Diacetamido-butan | 90152-34-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,3-Diacetamido-butan
• 英文别名: N-(3-acetamidobutan-2-yl)acetamide
• CAS: 90152-34-4
• 化学式: C₈H₁₆N₂O₂
• 分子量: 172.227
• InChiKey: KNXZKRNQFIYFGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  乙酸酐 、 丁烷-2,3-二胺 生成 2,3-Diacetamido-butan
  参考文献：
  名称：

  Wiemann,J. et al., Bulletin de la Societe Chimique de France, 1967, p. 3920 - 3923

  摘要：

  DOI：

文献信息

• POLYAMIDE-IMIDE BLOCK COPOLYMER, METHOD FOR PREPARING SAME, AND POLYAMIDE-IMIDE FILM COMPRISING SAME
  申请人：LG Chem, Ltd.

  公开号：EP3910003A1

  公开（公告）日：2021-11-17

  The polyamide-imide block copolymer according to the present invention makes it possible to provide a polyamide-imide film having excellent thermal stability and chemical resistance and, at the same time, having excellent mechanical properties.

  根据本发明的聚酰胺-酰亚胺嵌段共聚物，可以提供具有优异热稳定性和耐化学性的聚酰胺-酰亚胺薄膜，同时还具有优异的机械性能。
• US7342083B2
  申请人：——

  公开号：US7342083B2

  公开（公告）日：2008-03-11
• US7385012B2
  申请人：——

  公开号：US7385012B2

  公开（公告）日：2008-06-10
• [EN] POLYAMIDE-IMIDE BLOCK COPOLYMER, METHOD FOR PREPARING SAME, AND POLYAMIDE-IMIDE FILM COMPRISING SAME<br/>[FR] COPOLYMÈRE SÉQUENCÉ DE POLYAMIDE-IMIDE, SON PROCÉDÉ DE PRÉPARATION ET FILM POLYAMIDE-IMIDE LE COMPRENANT<br/>[KO] 폴리아미드-이미드 블록 공중합체, 이의 제조방법 및 이를 포함하는 폴리아미드-이미드 필름
  申请人：LG CHEMICAL LTD

  公开号：WO2020209625A1

  公开（公告）日：2020-10-15

  본 발명에 따른 폴리아미드-이미드 블록 공중합체는, 열적 안정성 및 내화학성이 우수하고 동시에 기계적 물성이 뛰어난, 폴리이미드-이미드 필름의 제공을 가능케 한다.
• [EN] SPECIFIC CONJUGATION OF AN ANTIBODY<br/>[FR] CONJUGAISON SPÉCIFIQUE D'UN ANTICORPS
  申请人：[en]HANGZHOU DAC BIOTECH CO., LTD.

  公开号：WO2022078524A2

  公开（公告）日：2022-04-21

  The invention relates to a process for preparing a homogeneous conjugate of an antibody or antibody-like protein via linkage of cysteine sites between heavy-light chains in the IgG antibody or antibody-like protein. The present invention also relates to methods of making the conjugates in a specific manner comprising either generation of specific thiols of an antibody or antibody-like protein agent, followed by reaction with drug/linker complexes, or generation of specific thiols of an antibody or antibody-like protein agent and conjugation of a synthetic linker-drug assembly with the thiols simultaneously in one pot reaction, to provide conjugates with over 75%, in most cases more than 80%of payloads linked at the specific cysteine sites between heavy-light chains of the IgG antibody or antibody-like protein. It also relates to methods of using the homogeneous conjugate in targeted prophylaxis or treatment of cancer, infection and immunological disorders.